Incyte Genomics of Palo Alto, Calif., and Eli Lilly of Indianapolis have expanded an agreement to collaborate on accelerating the development of therapeutic proteins. Under the terms of the new agreement, Eli Lilly and Incyte will focus on identifying and selecting secreted molecules that are strong candidates for therapeutic protein development. Eli Lilly will also obtain options to license multiple therapeutic protein patents from Incyte.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.